Your session is about to expire
← Back to Search
Modified CAR T Cells for Ovarian Cancer
Study Summary
This trial is testing a new cancer treatment that uses modified immune cells to target and kill ovarian cancer cells.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is there an open call for participants in this trial?
"Evidenced by the clinicaltrials.gov page, this trial is currently open to participants. The medical experiment was initiated on April 30th 2019 and its details were most recently updated as of June 28th 2022."
What potential adverse effects could arise from the use of PRGN-3005 UltraCAR-T cells?
"The safety of PRGN-3005 UltraCAR-T cells is deemed to be a 1 on the scale, as this phase one trial only has limited data that supports its efficacy and security."
What is the total sample size for this medical trial?
"Affirmative. According to clinicaltrials.gov, the research study went live on April 30th 2019 and was last revised on June 28th 2022. 71 individuals are being recruited from one medical centre for this trial."
Share this study with friends
Copy Link
Messenger